The short version of IGF-1 marker fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-05 and is reviewed periodically as new material appears.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
The protective effect of breastfeeding against obesity is consistent, though small, across many studies. A 2013 longitudinal study reported less obesity at ages two and four years among infants who were breastfed for at least four months.
The coastal taipan is the second-longest venomous snake in Australia after the king brown snake (Pseudechis australis). Adult specimens of this species typically attain sexual maturity around 1.2 m (3.9 ft) in total length (including tail). More mature specimens can grow to between 1.5 and 2.0 m (4.9 and 6.6 ft). Other taipans, including the inland taipan, attain broadly similar sizes, although they tend to be slightly smaller in average size. A specimen of an average 2.0 m (6.6 ft) total length weighs around 3.0 kg (6.6 lb). According to the Queensland Museum, the longest recorded total length for the coastal taipan was a specimen that was 2.9 m (9.5 ft) and weighed 6.5 kg (14 lb). Though exceptionally rare, much larger specimens are widely believed to exist, including specimens of as much as 3.3 m (11 ft). O. scutellatus has a long and narrow head with an angular brow and is lighter-coloured on the face. The body is slender and colouration can vary. It is often uniformly light olive or reddish-brown in colour, but some specimens may be dark gray to black. The colouration is lighter on the sides of the body, and the ventral side (the belly) is usually a creamy-white to a pale light yellow in colour, and is often marked with orange or pink flecks. Individuals undergo a seasonal change in colour, becoming darker in winter and fading in summer. The eyes are large, round, and are light brown or even hazel in colour with large pupils. As a large, brownish snake, the coastal taipan resembles the eastern brown snake (Pseudonaja textilis), northern brown snake (P.
In May 1878 Eddy brought a case against Daniel Spofford, in Salem, Massachusetts, for practicing mesmerism. It came to be known as the second Salem witchcraft trial. The case was filed in the name of one of Spofford's patients, Lucretia Brown, who said that he had bewitched her, though Eddy appeared in court on Brown's behalf. In preparation for the hearing, Eddy organized a 24-hour watch at 8 Broad Street, during which she asked 12 students to think about Spofford for two hours each and block malicious mesmerism from him. She arrived at the court with 20 supporters, including Amos Bronson Alcott (a "cloud of witnesses," according to the Boston Globe), but Judge Horace Gray dismissed the case. The attempt to have Spofford tried was not the end of the dispute. In October 1878 Eddy's husband and another student, Edward Arens, were charged with conspiring to murder Spofford. A barman said they had offered him $500 to do it; after a complex series of claims and counter-claims, the charges were dropped when a witness retracted his statement. Eddy attributed the allegation to a plot by former students to undermine sales of the second edition of Science and Health, just published. Her lawyer had to apply for an attachment order against her house to collect his fee.
Photosynthesizing plants, algae, and cyanobacteria synthesize tocochromanols, the chemical family of compounds made up of four tocopherols and four tocotrienols; in a nutrition context this family is referred to as Vitamin E. Biosynthesis starts with formation of the closed-ring part of the molecule as homogentisic acid (HGA). The side chain is attached (saturated for tocopherols, polyunsaturated for tocotrienols). The pathway for both is the same, so that gamma- is created and from that alpha-, or delta- is created and from that the beta- compounds. Biosynthesis takes place in the plastids. The main reason plants synthesize tocochromanols appears to be for antioxidant activity. Different parts of plants, and different species, are dominated by different tocochromanols. The predominant form in leaves, and hence leafy green vegetables, is α-tocopherol. Located in chloroplast membranes in close proximity to the photosynthetic process, they protect against damage from the ultraviolet radiation of sunlight. Under normal growing conditions, the presence of α-tocopherol does not appear to be essential, as there are other photo-protective compounds; plants that, through mutations, have lost the ability to synthesize α-tocopherol demonstrate normal growth. However, under stressed growing conditions such as drought, elevated temperature, or salt-induced oxidative stress, the plants' physiological status is superior if it has the normal synthesis capacity. Seeds are lipid-rich to provide energy for germination and early growth.
Evelyn Greechan, Senior Traffic Warden, City of Glasgow Police. For services to Road Safety. Ian Greenlaw, Support Grade Band 1, Her Majesty's Customs and Excise. Brian Gregory, Facilities Manager, Sussex Police. For services to the Police. Sylvia Gladys Grove, Office Support Grade Band 2, Home Office. Alan Joseph Gruar, Training Manager, Lucas Aerospace, Wolverhampton Training Centre, LucasVarity plc. For services to Training. Leslie Gurney. For services to the community in Stockport, Cheshire. Jessie Haggarty. For services to Highland Dancing. Jonathan Ian Hague, Detective Inspector, Metropolitan Police. For services to the Police. Alfred Hall. For services to the World Ploughing Organisation. Arthur Charles Hall. For services to the community in Walton-on-Thames, Surrey. Eileen Hall, Administrative Officer, Department of Social Security. Edna Hilda Knight Hallatt, Governor, Newcastle-under-Lyme School, Staffordshire. For services to Education. Mae Hamilton, Administrative Officer, Home Office. Brenda Margaret Hancock, lately Personal Secretary, Health and Safety Executive, Department of the Environment Angela Kathenne Hanley, Training Manager, First Aid Centre, London Transport. For services to Public Transport. Hilda Harding. For services to Mind and to the Elderly and Disadvantaged in Sutton, Surrey. Anthony Shannon Harman. For services to Agriculture and to the British Charolais Cattle Society. Susan Gladys Harper, Practice Nurse (Sister), Roslin Medical Centre, Midlothian. For services to Health Care. David Harris.
Sources: en.wikipedia.org
The primary function of the thyroid is the production of the iodine-containing thyroid hormones, triiodothyronine (T3) and thyroxine or tetraiodothyronine (T4) and the peptide hormone calcitonin. The thyroid hormones are created from iodine and tyrosine. T3 is so named because it contains three atoms of iodine per molecule and T4 contains four atoms of iodine per molecule. The thyroid hormones have a wide range of effects on the human body. These include:
The (Princely) County of Tyrol was an estate of the Holy Roman Empire established about 1140. After 1253, it was ruled by the House of Gorizia and from 1363 by the House of Habsburg. In 1804, the County of Tyrol, unified with the secularised prince-bishoprics of Trent and Brixen, became a crown land of the Austrian Empire, then was part of Bavaria from 1805 to 1814 when it returned to Austrian rule. From 1867, it was a Cisleithanian crown land of Austria-Hungary. Today the territory of the historic crown land is divided between the Italian autonomous region of Trentino-Alto Adige/Südtirol and the Austrian state of Tyrol. The two parts are today associated again in the Tyrol–South Tyrol–Trentino Euroregion.
Breeding onset occurs at about 50 days of age in both females and males, although females may have their first estrus at 25–40 days. Mice are polyestrous and breed year round; ovulation is spontaneous. The duration of the estrous cycle is 4–5 days and lasts about 12 hours, occurring in the evening. Vaginal smears are useful in timed matings to determine the stage of the estrous cycle. Mating can be confirmed by the presence of a copulatory plug in the vagina up to 24 hours post-copulation. The presence of sperm on a vaginal smear is also a reliable indicator of mating. The average gestation period is 20 days. A fertile postpartum estrus occurs 14–24 hours following parturition, and simultaneous lactation and gestation prolongs gestation by 3–10 days, owing to delayed implantation. The average litter size is 10–12 during optimum production, but this is highly strain-dependent. In general, inbred mice tend to have longer gestation periods and smaller litters than outbred and hybrid mice. The young are called pups and weigh 0.5–1.5 g (0.018–0.053 oz) at birth, are hairless, and have closed eyelids and ears. Pups are weaned at 3 weeks of age, when they weigh about 10–12 g (0.35–0.42 oz). If the female does not mate during the postpartum estrus, she resumes cycling 2–5 days post-weaning. Newborn males are distinguished from newborn females by their greater anogenital distance and larger genital papilla. This is usually observed by lifting the tails of littermates and comparing perinea.
The OSA frequency increase with age for the women, and is in particular linked to the onset of menopause and associated hormonal changes. The mortality is higher for women. If studied carefully in a sleep lab by polysomnography (formal "sleep study"), it is believed that approximately 1 in 5 American adults would have at least mild OSA. In the US, some studies report that it is more frequent among the Hispanic and African American population than among the white population.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.